In vitro and in silico tools to assess extent of cellular uptake and lysosomal sequestration of respiratory drugs in human alveolar macrophages

Molecular Pharmaceutics

Volumn 14, Issue 4, 2017, Pages 1033-1046

  Ufuk, Ayşe ^a   Assmus, Frauke ^a   Francis, Laura ^a   Plumb, Jonathan ^b   Damian, Valeriu ^c   Gertz, Michael ^a,d   Houston, J Brian ^a   Galetin, Aleksandra ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Drug accumulation; Human alveolar macrophages; In silico cell model; Lysosomal sequestration; NR8383

Indexed keywords

AMMONIUM CHLORIDE; BUDESONIDE; CLARITHROMYCIN; FENOTEROL; FORMOTEROL; IMIPRAMINE; IPRATROPIUM BROMIDE; LIPOSOME; RIFAMPICIN; TERBUTALINE; TIOTROPIUM BROMIDE; DRUG; PHOSPHOLIPID;

ARTICLE; CELLULAR DISTRIBUTION; COMPARTMENT MODEL; COMPUTER MODEL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG UPTAKE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIPOSOMAL DELIVERY; LUNG ALVEOLUS MACROPHAGE; LUNG CELL LINE; LYSOSOME; NR8383 CELL LINE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; AGED; ANIMAL; CELL LINE; COMPUTER SIMULATION; DRUG EFFECTS; FEMALE; MALE; METABOLISM; MIDDLE AGED; RAT; TISSUE DISTRIBUTION;

AGED; ANIMALS; CELL LINE; CLARITHROMYCIN; COMPUTER SIMULATION; FEMALE; HUMANS; IMIPRAMINE; LYSOSOMES; MACROPHAGES, ALVEOLAR; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; PHOSPHOLIPIDS; RATS; TISSUE DISTRIBUTION;

EID: 85019020278     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.6b00908     Document Type: Article

References (69)

1. Rodgers, T.; Leahy, D.; Rowland, M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J. Pharm. Sci. 2005, 94 (6), 1259-76.
2. Reasor, M. J.; Hastings, K. L.; Ulrich, R. G. Drug-induced phospholipidosis: issues and future directions. Expert Opin. Drug Saf. 2006, 5 (4), 567-83.
3. Duvvuri, M.; Krise, J. P. A novel assay reveals that weakly basic model compounds concentrate in lysosomes to an extent greater than pH-partitioning theory would predict. Mol. Pharmaceutics 2005, 2 (6), 440-8.
4. Chen, V. Y.; Rosania, G. R. The great multidrug-resistance paradox. ACS Chem. Biol. 2006, 1 (5), 271-3.
5. Logan, R.; Funk, R. S.; Axcell, E.; Krise, J. P. Drug-drug interactions involving lysosomes: mechanisms and potential clinical implications. Expert Opin. Drug Metab. Toxicol. 2012, 8 (8), 943-58.
6. Logan, R.; Kong, A.; Krise, J. P. Evaluating the roles of autophagy and lysosomal trafficking defects in intracellular distribution-based drug-drug interactions involving lysosomes. J. Pharm. Sci. 2013, 102 (11), 4173-80.
7. Daniel, W. A.; Wojcikowski, J. Lysosomal trapping as an important mechanism involved in the cellular distribution of perazine and in pharmacokinetic interaction with antidepressants. Eur. Neuropsychopharmacol. 1999, 9 (6), 483-91.
8. Bäckström, E.; Boger, E.; Lundqvist, A.; Hammarlund-Udenaes, M.; Friden, M. Lung Retention by Lysosomal Trapping of Inhaled Drugs Can Be Predicted In Vitro With Lung Slices. J. Pharm. Sci. 2016, 105 (11), 3432-3439.
9. Chu, X.; Korzekwa, K.; Elsby, R.; Fenner, K.; Galetin, A.; Lai, Y.; Matsson, P.; Moss, A.; Nagar, S.; Rosania, G. R.; Bai, J. P.; Polli, J. W.; Sugiyama, Y.; Brouwer, K. L. Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin. Pharmacol. Ther. 2013, 94 (1), 126-41.
10. Zhang, X.; Shedden, K.; Rosania, G. R. A cell-based molecular transport simulator for pharmacokinetic prediction and cheminformatic exploration. Mol. Pharmaceutics 2006, 3 (6), 704-16.
11. Friden, M.; Bergstrom, F.; Wan, H.; Rehngren, M.; Ahlin, G.; Hammarlund-Udenaes, M.; Bredberg, U. Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods. Drug Metab. Dispos. 2011, 39 (3), 353-62.
12. Ménochet, K.; Kenworthy, K. E.; Houston, J. B.; Galetin, A. Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model. J. Pharmacol. Exp. Ther. 2012, 341 (1), 2-15.
13. Nagar, S.; Tucker, J.; Weiskircher, E. A.; Bhoopathy, S.; Hidalgo, I. J.; Korzekwa, K. Compartmental models for apical efflux by P-glycoprotein-part 1: evaluation of model complexity. Pharm. Res. 2014, 31 (2), 347-59.
14. Ghosh, A.; Maurer, T. S.; Litchfield, J.; Varma, M. V.; Rotter, C.; Scialis, R.; Feng, B.; Tu, M.; Guimaraes, C. R.; Scott, D. O. Toward a unified model of passive drug permeation II: the physiochemical determinants of unbound tissue distribution with applications to the design of hepatoselective glucokinase activators. Drug Metab. Dispos. 2014, 42 (10), 1599-610.
15. Korzekwa, K. R.; Nagar, S.; Tucker, J.; Weiskircher, E. A.; Bhoopathy, S.; Hidalgo, I. J. Models to predict unbound intracellular drug concentrations in the presence of transporters. Drug Metab. Dispos. 2012, 40 (5), 865-76.
16. Trapp, S.; Rosania, G. R.; Horobin, R. W.; Kornhuber, J. Quantitative modeling of selective lysosomal targeting for drug design. Eur. Biophys. J. 2008, 37 (8), 1317-28.
17. Trapp, S.; Horobin, R. W. A predictive model for the selective accumulation of chemicals in tumor cells. Eur. Biophys. J. 2005, 34 (7), 959-66.
18. Hallifax, D.; Houston, J. B. Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction. Drug Metab. Dispos. 2007, 35 (8), 1325-32.
19. Heyneman, C. A.; Reasor, M. J. Role of the alveolar macrophage in the induction of pulmonary phospholipidosis by chlorphentermine. II. Drug uptake into cells in vitro. J. Pharmacol. Exp. Ther. 1986, 236 (1), 60-4.
20. Antonini, J. M.; Reasor, M. J. Accumulation of amiodarone and desethylamiodarone by rat alveolar macrophages in cell culture. Biochem. Pharmacol. 1991, 42 (Suppl.1), S151-S156.
21. Togami, K.; Chono, S.; Morimoto, K. Distribution characteristics of clarithromycin and azithromycin, macrolide antimicrobial agents used for treatment of respiratory infections, in lung epithelial lining fluid and alveolar macrophages. Biopharm. Drug Dispos. 2011, 32 (7), 389-97.
22. Togami, K.; Chono, S.; Morimoto, K. Subcellular Distribution of Azithromycin and Clarithromycin in Rat Alveolar Macrophages (NR8383) in Vitro. Biol. Pharm. Bull. 2013, 36 (9), 1494-9.
23. Togami, K.; Chono, S.; Seki, T.; Morimoto, K. Distribution characteristics of telithromycin, a novel ketolide antimicrobial agent applied for treatment of respiratory infection, in lung epithelial lining fluid and alveolar macrophages. Drug Metab. Pharmacokinet. 2009, 24 (5), 411-7.
24. Togami, K.; Chono, S.; Seki, T.; Morimoto, K. Intracellular pharmacokinetics of telithromycin, a ketolide antibiotic, in alveolar macrophages. J. Pharm. Pharmacol. 2010, 62 (1), 71-5.
25. Ufuk, A.; Somers, G.; Houston, J. B.; Galetin, A. In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383. Pharm. Res. 2015, 32 (12), 3937-51.
26. Nadanaciva, S.; Lu, S.; Gebhard, D. F.; Jessen, B. A.; Pennie, W. D.; Will, Y. A high content screening assay for identifying lysosomotropic compounds. Toxicol. In Vitro 2011, 25 (3), 715-23.
27. Higham, A.; Booth, G.; Lea, S.; Southworth, T.; Plumb, J.; Singh, D. The effects of corticosteroids on COPD lung macrophages: a pooled analysis. Respir. Res. 2015, 16, 98.
28. Southworth, T.; Metryka, A.; Lea, S.; Farrow, S.; Plumb, J.; Singh, D. IFN-gamma synergistically enhances LPS signalling in alveolar macrophages from COPD patients and controls by corticosteroid-resistant STAT1 activation. Br. J. Pharmacol. 2012, 166 (7), 2070-83.
29. Plumb, J.; Robinson, L.; Lea, S.; Banyard, A.; Blaikley, J.; Ray, D.; Bizzi, A.; Volpi, G.; Facchinetti, F.; Singh, D. Evaluation of glucocorticoid receptor function in COPD lung macrophages using beclomethasone-17-monopropionate. PLoS One 2013, 8 (5), e64257.
30. Hallifax, D.; Houston, J. B. Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance. Drug Metab. Dispos. 2006, 34 (11), 1829-36.
31. Yabe, Y.; Galetin, A.; Houston, J. B. Kinetic characterization of Rat Hepatic Uptake of 16 Actively Transported Drugs. Drug Metab. Dispos. 2011, 39, 1808.
32. Harris, J. O.; Swenson, E. W.; Johnson, J. E., 3rd Human alveolar macrophages: comparison of phagocytic ability, glucose utilization, and ultrastructure in smokers and nonsmokers. J. Clin. Invest. 1970, 49 (11), 2086-96.
33. Reynolds, H. Y.; Newball, H. H. Analysis of proteins and respiratory cells obtained from human lungs by bronchial lavage. J. Lab. Clin. Med. 1974, 84 (4), 559-73.
34. Territo, M. C.; Golde, D. W. The function of human alveolar macrophages. J. Reticuloendothelial Soc. 1979, 25 (1), 111-20.
35. Pauletti, M.; Wunderli-Allenspach, H. Partition coefficients in vitro: artificial membranes as a standardized distribution model. Eur. J. Pharm. Sci. 1994, 1 (5), 273-282.
36. Austin, R. P.; Davis, A. M.; Manners, C. N. Partitioning of ionizing molecules between aqueous buffers and phospholipid vesicles. J. Pharm. Sci. 1995, 84 (10), 1180-3.
37. Krämer, S. D.; Wunderli-Allenspach, H. The pH-dependence in the partitioning behaviour of (RS)-[3H]propranolol between MDCK cell lipid vesicles and buffer. Pharm. Res. 1996, 13 (12), 1851-5.
38. Ottiger, C.; Wunderli-Allenspach, H. Partition behaviour of acids and bases in a phosphatidylcholine liposome-buffer equilibrium dialysis system. Eur. J. Pharm. Sci. 1997, 5 (4), 223-231.
39. Avdeef, A.; Box, K. J.; Comer, J. E.; Hibbert, C.; Tam, K. Y. pH-metric logP 10. Determination of liposomal membrane-water partition coefficients of ionizable drugs. Pharm. Res. 1998, 15 (2), 209-15.
40. Fruttero, R.; Caron, G.; Fornatto, E.; Boschi, D.; Ermondi, G.; Gasco, A.; Carrupt, P. A.; Testa, B. Mechanisms of liposomes/water partitioning of (p-methylbenzyl)alkylamines. Pharm. Res. 1998, 15 (9), 1407-13.
41. Krämer, S. D.; Braun, A.; Jakits-Deiser, C.; Wunderli-Allenspach, H. Towards the predictability of drug-lipid membrane interactions: the pH-dependent affinity of propanolol to phosphatidylinositol containing liposomes. Pharm. Res. 1998, 15 (5), 739-44.
42. Balon, K.; Riebesehl, B. U.; Muller, B. W. Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption. Pharm. Res. 1999, 16 (6), 882-8.
43. Marenchino, M.; Alpstag-Wohrle, A. L.; Christen, B.; Wunderli-Allenspach, H.; Kramer, S. D. Alpha-tocopherol influences the lipid membrane affinity of desipramine in a pH-dependent manner. Eur. J. Pharm. Sci. 2004, 21 (2-3), 313-21.
44. Fletcher, K.; Wyatt, I. The composition of lung lipids after poisoning with paraquat. Br. J. Exp. Pathol. 1970, 51 (6), 604-10.
45. Sahu, S.; Lynn, W. S. Lipid composition of human alveolar macrophages. Inflammation 1977, 2 (2), 83-91.
46. Korn, E. D. Structure of biological membranes. Science 1966, 153 (3743), 1491-8.
47. Honeybourne, D.; Kees, F.; Andrews, J. M.; Baldwin, D.; Wise, R. The levels of clarithromycin and its 14-hydroxy metabolite in the lung. Eur. Respir. J. 1994, 7 (7), 1275-80.
48. Conte, J. E., Jr.; Golden, J. A.; Duncan, S.; McKenna, E.; Zurlinden, E. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob. Agents Chemother. 1995, 39 (2), 334-8.
49. Patel, K. B.; Xuan, D.; Tessier, P. R.; Russomanno, J. H.; Quintiliani, R.; Nightingale, C. H. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob. Agents Chemother. 1996, 40 (10), 2375-9.
50. Rodvold, K.; Gotfried, M.; Danziger, L.; Servi, R. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob. Agents Chemother. 1997, 41 (6), 1399-1402.
51. Hand, W. L.; Corwin, R. W.; Steinberg, T. H.; Grossman, G. D. Uptake of antibiotics by human alveolar macrophages. Am. Rev. Respir. Dis. 1984, 129 (6), 933-7.
52. Cohen, A. B.; Cline, M. J. The human alveolar macrophage: isolation, cultivation in vitro, and studies of morphologic and functional characteristics. J. Clin. Invest. 1971, 50 (7), 1390-8.
53. Pratt, S. A.; Smith, M. H.; Ladman, A. J.; Finley, T. N. The ultrastructure of alveolar macrophages from human cigarette smokers and nonsmokers. Lab. Invest. 1971, 24 (5), 331-8.
54. Hocking, W. G.; Golde, D. W. The pulmonary-alveolar macrophage (first of two parts). N. Engl. J. Med. 1979, 301 (11), 580-7.
55. Taylor, A. E.; Finney-Hayward, T. K.; Quint, J. K.; Thomas, C. M.; Tudhope, S. J.; Wedzicha, J. A.; Barnes, P. J.; Donnelly, L. E. Defective macrophage phagocytosis of bacteria in COPD. Eur. Respir. J. 2010, 35 (5), 1039-47.
56. Hodge, S.; Hodge, G.; Ahern, J.; Jersmann, H.; Holmes, M.; Reynolds, P. N. Smoking alters alveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 2007, 37 (6), 748-55.
57. van der Deen, M.; de Vries, E. G.; Visserman, H.; Zandbergen, W.; Postma, D. S.; Timens, W.; Timmer-Bosscha, H. Cigarette smoke extract affects functional activity of MRP1 in bronchial epithelial cells. J. Biochem. Mol. Toxicol. 2007, 21 (5), 243-51.
58. Kosol, S.; Schrank, E.; Krajacic, M. B.; Wagner, G. E.; Meyer, N. H.; Gobl, C.; Rechberger, G. N.; Zangger, K.; Novak, P. Probing the interactions of macrolide antibiotics with membrane-mimetics by NMR spectroscopy. J. Med. Chem. 2012, 55 (11), 5632-6.
59. Joshi, U. M.; Kodavanti, P. R.; Coudert, B.; Dwyer, T. M.; Mehendale, H. M. Types of interaction of amphiphilic drugs with phospholipid vesicles. J. Pharmacol. Exp. Ther. 1988, 246 (1), 150-7.
60. Fisar, Z.; Fuksova, K.; Velenovska, M. Binding of imipramine to phospholipid bilayers using radioligand binding assay. Gen. Physiol. Biophys. 2004, 23 (1), 77-99.
61. Vavricka, S. R.; Van Montfoort, J.; Ha, H. R.; Meier, P. J.; Fattinger, K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology (Hoboken, NJ, U. S.) 2002, 36 (1), 164-72.
62. Nakanishi, T.; Haruta, T.; Shirasaka, Y.; Tamai, I. Organic cation transporter-mediated renal secretion of ipratropium and tiotropium in rats and humans. Drug Metab. Dispos. 2011, 39 (1), 117-22.
63. Nickel, S.; Clerkin, C. G.; Selo, M. A.; Ehrhardt, C. Transport mechanisms at the pulmonary mucosa: implications for drug delivery. Expert Opin. Drug Delivery 2016, 13 (5), 667-90.
64. Ong, H. X.; Traini, D.; Bebawy, M.; Young, P. M. Ciprofloxacin is actively transported across bronchial lung epithelial cells using a Calu-3 air interface cell model. Antimicrob. Agents Chemother. 2013, 57 (6), 2535-40.
65. Nakamura, T.; Nakanishi, T.; Haruta, T.; Shirasaka, Y.; Keogh, J. P.; Tamai, I. Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol. Pharmaceutics 2010, 7 (1), 187-95.
66. Moreau, A.; Le Vee, M.; Jouan, E.; Parmentier, Y.; Fardel, O. Drug transporter expression in human macrophages. Fundam. Clin. Pharmacol. 2011, 25 (6), 743-52.
67. Ruark, C. D.; Hack, C. E.; Robinson, P. J.; Mahle, D. A.; Gearhart, J. M. Predicting passive and active tissue:plasma partition coefficients: interindividual and interspecies variability. J. Pharm. Sci. 2014, 103 (7), 2189-98.
68. Schmitt, W. General approach for the calculation of tissue to plasma partition coefficients. Toxicol. In Vitro 2008, 22 (2), 457-67.
69. Rodgers, T.; Rowland, M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J. Pharm. Sci. 2006, 95 (6), 1238-57.